Pomella (Punica granatum extract)

Pomella is a standardized Punica granatum (pomegranate) extract concentrated in punicalagins and ellagic acid, polyphenols that are metabolized by gut bacteria into urolithin A. This urolithin A drives its primary mechanisms, including antioxidant defense, gut microbiome modulation, and potential immunomodulatory activity.

Origin & History

Pomella is a patented branded extract derived from pomegranate fruit (Punica granatum L.), native to the Middle East. It is produced through extraction methods focusing on ellagitannin-rich fractions, standardized to contain 20% punicalagins by HPLC and total polyphenols.

Historical & Cultural Context

Pomegranate has been used in traditional medicine systems like Ayurveda and Unani for over 2,000 years to treat inflammation, diarrhea, and oxidative conditions. While the fruit has extensive traditional use, Pomella as a branded standardized extract lacks historical precedent.

Health Benefits

• Supports gut microbiota balance and increases beneficial short-chain fatty acids (Evidence: RCT, n=40)
• Elevates urolithin A levels for potential immunomodulatory effects (Evidence: RCT, n=40)
• Provides potent antioxidant activity through DPPH radical scavenging up to 81% (Evidence: In-vitro studies)
• May inhibit LDL oxidation by up to 93.7% (Evidence: Laboratory studies)
• Potentially reduces inflammation through nitric oxide and iNOS suppression (Evidence: Cell culture studies)

How It Works

Punicalagins in Pomella are hydrolyzed in the gut to ellagic acid, which colonic microflora further convert into urolithin A via sequential lactonization and dehydroxylation steps. Urolithin A activates Nrf2-mediated antioxidant response elements, upregulating cytoprotective enzymes such as heme oxygenase-1 (HO-1) and superoxide dismutase (SOD). Additionally, urolithin A modulates NF-κB signaling and promotes mitophagy through PINK1/Parkin pathway activation, contributing to its immunomodulatory and cellular homeostasis effects.

Scientific Research

A prospective randomized, double-blind, placebo-controlled study (n=40 healthy adults) tested 75 mg punicalagins from Pomella daily for 4 weeks, showing significant shifts in gut microbiota composition, increased plasma short-chain fatty acids, and elevated urolithin A levels (PMID: 38139000). While specific RCTs on Pomella are limited, related pomegranate extract studies demonstrate anti-inflammatory effects in animal models.

Clinical Summary

A randomized controlled trial (n=40) demonstrated that Pomella supplementation significantly elevated plasma urolithin A levels and improved short-chain fatty acid (SCFA) production, indicating favorable shifts in gut microbiota composition. The same RCT reported immunomodulatory effects attributable to elevated urolithin A, though mechanistic endpoints were exploratory. In vitro studies have quantified DPPH free-radical scavenging activity at up to 81%, supporting robust antioxidant capacity. Overall, the clinical evidence base is promising but limited by small sample sizes and a need for larger, longer-duration trials.

Nutritional Profile

Pomella is a standardized extract of Punica granatum (pomegranate) fruit, typically standardized to ≥30% punicalagins (primary bioactive ellagitannins) and ≥50–70% total polyphenols. Key bioactive compounds include: **Ellagitannins** – punicalagin α and β (collectively 250–350 mg per typical 500 mg dose), punicalin, and pedunculagin, which are hydrolyzed in the gut to release ellagic acid; **Ellagic acid** – approximately 2–5% free form in the extract, with substantially more liberated upon gastrointestinal hydrolysis of parent ellagitannins; **Anthocyanins** – trace amounts of cyanidin-3-glucoside and delphinidin-3-glucoside (typically <1%); **Gallic acid and other hydroxybenzoic acids** – present at approximately 1–3% of extract weight; **Flavonoids** – minor quantities of quercetin, kaempferol, and luteolin glycosides. The extract contains negligible macronutrients (protein <1%, fat <0.5%, carbohydrates ~5–10% primarily from residual sugars and fiber fragments per serving). Mineral content is minimal but may include trace potassium (~0.5–1.5 mg per dose) and trace iron. No significant vitamins are present at supplemental levels. **Bioavailability notes:** Punicalagins themselves have very low oral bioavailability (<0.1% absorbed intact) but are extensively hydrolyzed to ellagic acid in the upper GI tract. Ellagic acid is partially absorbed but undergoes significant colonic metabolism by gut microbiota (Gordonibacter and Ellagibacter spp.) to produce **urolithins** (primarily urolithin A, and to a lesser extent urolithins B, C, and D), which are the principal systemically bioavailable metabolites. Urolithin A reaches plasma concentrations of 0.5–18 µM depending on individual metabotype (metabotype A producers generate predominantly urolithin A glucuronide; approximately 40–60% of individuals are efficient urolithin A producers). Peak plasma urolithin levels occur 24–48 hours post-ingestion, reflecting colonic metabolism. The antioxidant capacity (ORAC) of the extract is approximately 4,000–6,000 µmol TE/g. DPPH radical scavenging activity reaches up to 81% at standard test concentrations. The extract demonstrates up to 93.7% inhibition of copper-induced LDL oxidation in laboratory assays, attributable primarily to punicalagins and ellagic acid acting synergistically.

Preparation & Dosage

Clinically studied dosage: 150-300 mg/day of standardized extract (containing 20% punicalagins, typically 75 mg punicalagins per dose). Standardization specified as 20% punicalagins by HPLC. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Probiotics, Prebiotics, Vitamin C, Green Tea Extract, Resveratrol

Safety & Interactions

Pomella is generally well tolerated at studied doses, with no serious adverse events reported in available RCT data; mild gastrointestinal discomfort is a possible side effect given its high polyphenol content. Punicalagins and ellagic acid may inhibit CYP3A4 and CYP2C9 enzymes, raising potential interaction concerns with anticoagulants such as warfarin, certain statins, and immunosuppressants like cyclosporine. Individuals taking blood-pressure-lowering medications should exercise caution, as pomegranate polyphenols have demonstrated mild antihypertensive effects that could produce additive hypotension. Safety data in pregnant or breastfeeding women are insufficient, and use during these periods should be discussed with a healthcare provider.